Details of the Drug

General Information of Drug (ID: DMZ7AMY)

Drug Name
Amivantamab
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Approved [1]
ATC Code
L01FX18: Amivantamab
L01FX: Other monoclonal antibodies and antibody drug conjugates
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
ADMET Property
Clearance
The clearance of drug is 360 +/- 144 mL/day [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 11.3 +/- 4.53 days [2]
Metabolism
The drug is metabolized to oligopeptides and amino acids [3]
Vd
The volume of distribution (Vd) of drug is 5.13 +/- 1.78 L [2]
Cross-matching ID
UNII
0JSR7Z0NB6
DrugBank ID
DB16695
TTD ID
DQ5X1Z

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [4]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Met (MET) DTT MET 1.08E-03 -0.24 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.
2 FDA Approved Drug Products: Rybrevant (Amivantamab-vmjw) Intravenous Injection
3 Veve MP, Wagner JL: Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.
4 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.